A Phase 2 interventional study of Obicetrapib 5mg and Ezetimibe 10mg in Dyslipidemias, High Cholesterol and Hypercholesterolemia, sponsored by NewAmsterdam Pharma. Completed at 9 sites in 2 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-04-24.
Sponsored by NewAmsterdam Pharma · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 98 studies testing ezetimibe in Hypercholesterolemia — 3 open to participants now, 4 under way, 1 of them phase 3. Ezetimibe · Hypercholesterolemia.
Among the 98 studies testing ezetimibe in Hypercholesterolemia, this one is the 63rd largest by enrollment of the 97 interventional ones that give a count, is the only one that started in 2021, is one of 7 in phase 2, and was the 91st registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →3 of the 98 studies testing ezetimibe in Hypercholesterolemia are open now, in 5 countries. Recruiting first, the newest first:
Chang Gung Memorial Hospital · Sites in Taiwan
Ages 20–100
Daiichi Sankyo · Sites in Germany, Italy, Spain
Ages 18+
Punjab Institute of Cardology · Sites in Pakistan
Ages 18+
By country, each count listing its studies:
Ezetimibe: first FDA approval 2002 (ZETIA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
98 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 1 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 112 is close to the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 148 across the 97 interventional studies. Of the 91 that completed or were terminated, 47 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
76 of 98 have an industry lead sponsor. The 10 most frequent:
NewAmsterdam Pharma is the lead sponsor of 20 studies on the registry; 3 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 8 (62%) have results posted.
NewAmsterdam Pharma has 7 studies filed under Hypercholesterolemia — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 98 studies testing ezetimibe in Hypercholesterolemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will be a placebo-controlled, double-blind, randomized, phase 2 study in participants with mild dyslipidemia to evaluate the efficacy, safety, and tolerability of obicetrapib and ezetimibe combination therapy.
This study will be a placebo-controlled, double-blind, randomized, phase 2 study in participants with mild dyslipidemia to evaluate the efficacy, safety, and tolerability of obicetrapib and ezetimibe combination therapy. The screening period for this study will take up to 2 weeks. Following the screening period, eligible patients will be randomized to placebo, 5 mg obicetrapib + 10 mg ezetimibe; 5 mg obicetrapib + placebo ezetimibe; or placebo obicetrapib + 10 mg ezetimibe for an 8 week treatment period. After the treatment period, patients will continue for a 4 week safety follow-up and a 8 week PK follow-up.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
This study's enrollment of 112 is close to the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Browse Hypercholesterolemia studies →NewAmsterdam Pharma is the lead sponsor of 20 studies on the registry; 3 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 8 (62%) have results posted.
Compared within Hypercholesterolemia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Dyslipidemias. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
One retest will be allowed, at which point if the retest result is no longer exclusionary, the participant may be randomized
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
placebo obicetrapib + placebo ezetimibe; once daily
Other: Placebo
5 mg obicetrapib + 10 mg ezetimibe; once daily
Drug: Obicetrapib 5mg · Drug: Ezetimibe 10mg
5 mg obicetrapib + placebo ezetimibe; once daily
Drug: Obicetrapib 5mg
placebo obicetrapib + 10 mg ezetimibe; once daily
Drug: Ezetimibe 10mg
tablet
Also known as: CETP inhibitor
tablet
Also known as: Antihyperlipidemic
tablet
Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Placebo [Friedewald]
Mean percent change in LDL-C from baseline to Day 57; LDL-C determined using the Friedewald formula
Time frame: 8 weeks
Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Placebo [Friedewald]
Median percent change in LDL-C from baseline to Day 57; LDL-C determined using the Friedewald formula
Time frame: 8 weeks
LS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Placebo [Friedewald]
LS Mean percent change in LDL-C from baseline to Day 57; LDL-C determined using the Friedewald formula
Time frame: 8 weeks
Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Placebo [PUC]
Mean percent change in LDL-C from baseline to Day 57; LDL-C measured using preparative ultracentrifugation (PUC)
Time frame: 8 weeks
Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Placebo [PUC]
Median percent change in LDL-C from baseline to Day 57; LDL-C measured using preparative ultracentrifugation (PUC)
Time frame: 8 weeks
LS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Placebo [PUC]
LS Mean percent change in LDL-C from baseline to Day 57; LDL-C measured using preparative ultracentrifugation (PUC)
Time frame: 8 weeks
Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib Monotherapy Compared to Placebo [Friedewald]
Mean percent change in LDL-C from baseline to Day 57; LDL-C determined using the Friedewald formula
Time frame: 8 weeks
Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib Monotherapy Compared to Placebo [Friedewald]
Median percent change in LDL-C from baseline to Day 57; LDL-C determined using the Friedewald formula
Time frame: 8 weeks
LS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib Monotherapy Compared to Placebo [Friedewald]
LS Mean percent change in LDL-C from baseline to Day 57; LDL-C determined using the Friedewald formula
Time frame: 8 weeks
Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib Monotherapy Compared to Placebo [PUC]
Mean percent change in LDL-C from baseline to Day 57; LDL-C measured using preparative ultracentrifugation (PUC)
Time frame: 8 weeks
Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib Monotherapy Compared to Placebo [PUC]
Median percent change in LDL-C from baseline to Day 57; LDL-C measured using preparative ultracentrifugation (PUC)
Time frame: 8 weeks
LS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib Monotherapy Compared to Placebo [PUC]
LS Mean percent change in LDL-C from baseline to Day 57; LDL-C measured using preparative ultracentrifugation (PUC)
Time frame: 8 weeks
Mean Percent Change in Apolipoprotein-B (ApoB) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Placebo
Mean percent change in ApoB from baseline to Day 57
Time frame: 8 weeks
Median Percent Change in Apolipoprotein-B (ApoB) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Placebo
Median percent change in ApoB from baseline to Day 57
Time frame: 8 weeks
LS Mean Percent Change in Apolipoprotein-B (ApoB) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Placebo
LS Mean percent change in ApoB from baseline to Day 57
Time frame: 8 weeks
Mean Percent Change in Apolipoprotein-B (ApoB) From Baseline to Day 57: Obicetrapib Monotherapy Compared to Placebo
Mean percent change in Apo-B from baseline to Day 57
Time frame: 8 weeks
Median Percent Change in Apolipoprotein-B (ApoB) From Baseline to Day 57: Obicetrapib Monotherapy Compared to Placebo
Median percent change in Apo-B from baseline to Day 57
Time frame: 8 weeks
LS Mean Percent Change in Apolipoprotein-B (ApoB) From Baseline to Day 57: Obicetrapib Monotherapy Compared to Placebo
LS Mean percent change in Apo-B from baseline to Day 57
Time frame: 8 weeks
Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Ezetimibe Monotherapy [Friedewald]
Mean percent change in LDL-C from baseline to Day 57; LDL-C determined using the Friedewald formula
Time frame: 8 weeks
Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Ezetimibe Monotherapy [Friedewald]
Median percent change in LDL-C from baseline to Day 57; LDL-C determined using the Friedewald formula
Time frame: 8 weeks
LS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Ezetimibe Monotherapy [Friedewald]
LS Mean percent change in LDL-C from baseline to Day 57; LDL-C determined using the Friedewald formula
Time frame: 8 weeks
Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib Monotherapy Compared to Ezetimibe Monotherapy [Friedewald]
Mean percent change in LDL-C from baseline to Day 57; LDL-C determined using the Friedewald formula
Time frame: 8 weeks
Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib Monotherapy Compared to Ezetimibe Monotherapy [Friedewald]
Median percent change in LDL-C from baseline to Day 57; LDL-C determined using the Friedewald formula
Time frame: 8 weeks
LS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib Monotherapy Compared to Ezetimibe Monotherapy [Friedewald]
LS Mean percent change in LDL-C from baseline to Day 57; LDL-C calculated using the Friedewald formula
Time frame: 8 weeks
Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Ezetimibe Monotherapy Compared to Placebo [Friedewald]
Mean percent change in LDL-C from baseline to Day 57; LDL-C determined using the Friedewald formula
Time frame: 8 weeks
Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Ezetimibe Monotherapy Compared to Placebo [Friedewald]
Median percent change in LDL-C from baseline to Day 57; LDL-C calculated using the Friedewald formula
Time frame: 8 weeks
LS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Ezetimibe Monotherapy Compared to Placebo [Friedewald]
LS Mean percent change in LDL-C from baseline to Day 57; LDL-C calculated using the Friedewald formula
Time frame: 8 weeks
Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Ezetimibe Monotherapy Compared to Placebo [PUC]
Mean percent change in LDL-C from baseline to Day 57; LDL-C measured using preparative ultracentrifugation (PUC)
Time frame: 8 weeks
Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Ezetimibe Monotherapy Compared to Placebo [PUC]
Median percent change in LDL-C from baseline to Day 57; LDL-C measured using preparative ultracentrifugation (PUC)
Time frame: 8 weeks
LS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Ezetimibe Monotherapy Compared to Placebo [PUC]
LS Mean percent change in LDL-C from baseline to Day 57; LDL-C measured using preparative ultracentrifugation (PUC)
Time frame: 8 weeks
Mean Percent Change in Apolipoprotein-B (ApoB) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Ezetimibe Monotherapy
Mean percent change in ApoB from baseline to Day 57
Time frame: 8 weeks
Median Percent Change in Apolipoprotein-B (ApoB) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Ezetimibe Monotherapy
Median percent change in ApoB from baseline to Day 57
Time frame: 8 weeks
LS Mean Percent Change in Apolipoprotein-B (ApoB) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Ezetimibe Monotherapy
LS Mean Percent change in ApoB from baseline to Day 57
Time frame: 8 weeks
234 participants were screened; out of 234, 112 participants were randomized. One participant in the ezetimibe 10 mg group was randomized in error and did not participate in the study or receive study drug
| Milestone | Placebo | Combination Therapy | Obicetrapib Monotherapy | Ezetimibe Monotherapy |
|---|---|---|---|---|
| Started | 28 | 27 | 28 | 29 |
| Completed | 26 | 22 | 26 | 24 |
| Not completed | 2 | 5 | 2 | 5 |
| Withdrew: Adverse event | 1 | 2 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 2 | 1 | 0 |
| Withdrew: Failed attempt to draw blood | 1 | 0 | 0 | 0 |
| Withdrew: Left the country | 0 | 0 | 1 | 2 |
| Withdrew: Randomized in error and did not receive study drug | 0 | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 1 |
| Withdrew: Moved away from study site | 0 | 1 | 0 | 0 |
Mean percent change in LDL-C from baseline to Day 57; LDL-C determined using the Friedewald formula
| percent change from baseline | Combination Therapy | Placebo |
|---|---|---|
| Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Placebo [Friedewald] | -45.63 ± 21.677 | -0.17 ± 12.682 |
Median percent change in LDL-C from baseline to Day 57; LDL-C determined using the Friedewald formula
| percent change from baseline | Combination Therapy | Placebo |
|---|---|---|
| Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Placebo [Friedewald] | -51.95 (-77.9 to 3.1) | -1.40 (-20.9 to 33.6) |
LS Mean percent change in LDL-C from baseline to Day 57; LDL-C determined using the Friedewald formula
| percent change from baseline | Combination Therapy | Placebo |
|---|---|---|
| LS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Placebo [Friedewald] | -43.55 ± 3.746 | 1.37 ± 3.604 |
Mean percent change in LDL-C from baseline to Day 57; LDL-C measured using preparative ultracentrifugation (PUC)
| percent change from baseline | Combination Therapy | Placebo |
|---|---|---|
| Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Placebo [PUC] | -44.38 ± 20.731 | -1.53 ± 15.105 |
Median percent change in LDL-C from baseline to Day 57; LDL-C measured using preparative ultracentrifugation (PUC)
| percent change from baseline | Combination Therapy | Placebo |
|---|---|---|
| Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Placebo [PUC] | -51.40 (-69.6 to 8.1) | -2.00 (-24.5 to 35.9) |
LS Mean percent change in LDL-C from baseline to Day 57; LDL-C measured using preparative ultracentrifugation (PUC)
| percent change from baseline | Combination Therapy | Placebo |
|---|---|---|
| LS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Placebo [PUC] | -44.10 ± 3.813 | -0.78 ± 4.012 |
Mean percent change in LDL-C from baseline to Day 57; LDL-C determined using the Friedewald formula
| percent change from baseline | Obicetrapib Monotherapy | Placebo |
|---|---|---|
| Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib Monotherapy Compared to Placebo [Friedewald] | -31.88 ± 18.860 | -0.17 ± 12.682 |
Median percent change in LDL-C from baseline to Day 57; LDL-C determined using the Friedewald formula
| percent change from baseline | Obicetrapib Monotherapy | Placebo |
|---|---|---|
| Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib Monotherapy Compared to Placebo [Friedewald] | -34.40 (-57.0 to 23.8) | -1.40 (-20.9 to 33.6) |
LS Mean percent change in LDL-C from baseline to Day 57; LDL-C determined using the Friedewald formula
| percent change from baseline | Obicetrapib Monotherapy | Placebo |
|---|---|---|
| LS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib Monotherapy Compared to Placebo [Friedewald] | -31.99 ± 3.686 | 1.37 ± 3.604 |
Mean percent change in LDL-C from baseline to Day 57; LDL-C measured using preparative ultracentrifugation (PUC)
| percent change from baseline | Obicetrapib Monotherapy | Placebo |
|---|---|---|
| Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib Monotherapy Compared to Placebo [PUC] | -27.94 ± 18.914 | -1.53 ± 15.105 |
Median percent change in LDL-C from baseline to Day 57; LDL-C measured using preparative ultracentrifugation (PUC)
| percent change from baseline | Obicetrapib Monotherapy | Placebo |
|---|---|---|
| Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib Monotherapy Compared to Placebo [PUC] | -30.10 (-56.7 to 19.1) | -2.00 (-24.5 to 35.9) |
LS Mean percent change in LDL-C from baseline to Day 57; LDL-C measured using preparative ultracentrifugation (PUC)
| percent change from baseline | Obicetrapib Monotherapy | Placebo |
|---|---|---|
| LS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib Monotherapy Compared to Placebo [PUC] | -28.98 ± 3.802 | -0.78 ± 4.012 |
Mean percent change in ApoB from baseline to Day 57
| percent change from baseline | Combination Therapy | Placebo |
|---|---|---|
| Mean Percent Change in Apolipoprotein-B (ApoB) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Placebo | -31.62 ± 15.521 | -1.17 ± 11.692 |
Median percent change in ApoB from baseline to Day 57
| percent change from baseline | Combination Therapy | Placebo |
|---|---|---|
| Median Percent Change in Apolipoprotein-B (ApoB) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Placebo | -34.75 (-53.0 to 8.9) | -0.90 (-19.8 to 25.4) |
LS Mean percent change in ApoB from baseline to Day 57
| percent change from baseline | Combination Therapy | Placebo |
|---|---|---|
| LS Mean Percent Change in Apolipoprotein-B (ApoB) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Placebo | -29.73 ± 2.730 | -0.11 ± 2.626 |
Mean percent change in Apo-B from baseline to Day 57
| percent change from baseline | Obicetrapib Monotherapy | Placebo |
|---|---|---|
| Mean Percent Change in Apolipoprotein-B (ApoB) From Baseline to Day 57: Obicetrapib Monotherapy Compared to Placebo | -22.15 ± 13.356 | -1.17 ± 11.692 |
Median percent change in Apo-B from baseline to Day 57
| percent change from baseline | Obicetrapib Monotherapy | Placebo |
|---|---|---|
| Median Percent Change in Apolipoprotein-B (ApoB) From Baseline to Day 57: Obicetrapib Monotherapy Compared to Placebo | -23.50 (-39.3 to 21.2) | -0.90 (-19.8 to 25.4) |
LS Mean percent change in Apo-B from baseline to Day 57
| percent change from baseline | Obicetrapib Monotherapy | Placebo |
|---|---|---|
| LS Mean Percent Change in Apolipoprotein-B (ApoB) From Baseline to Day 57: Obicetrapib Monotherapy Compared to Placebo | -22.46 ± 2.675 | -0.11 ± 2.626 |
Mean percent change in LDL-C from baseline to Day 57; LDL-C determined using the Friedewald formula
| percent change from baseline | Combination Therapy | Ezetimibe Monotherapy |
|---|---|---|
| Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Ezetimibe Monotherapy [Friedewald] | -45.63 ± 21.677 | -12.69 ± 21.316 |
Median percent change in LDL-C from baseline to Day 57; LDL-C determined using the Friedewald formula
| percent change from baseline | Combination Therapy | Ezetimibe Monotherapy |
|---|---|---|
| Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Ezetimibe Monotherapy [Friedewald] | -51.95 (-77.9 to 3.1) | -14.80 (-51.9 to 59.1) |
LS Mean percent change in LDL-C from baseline to Day 57; LDL-C determined using the Friedewald formula
| percent change from baseline | Combination Therapy | Ezetimibe Monotherapy |
|---|---|---|
| LS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Ezetimibe Monotherapy [Friedewald] | -43.55 ± 3.746 | -13.42 ± 3.675 |
Mean percent change in LDL-C from baseline to Day 57; LDL-C determined using the Friedewald formula
| percent change from baseline | Obicetrapib Monotherapy | Ezetimibe Monotherapy |
|---|---|---|
| Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib Monotherapy Compared to Ezetimibe Monotherapy [Friedewald] | -31.88 ± 18.860 | -12.69 ± 21.316 |
Median percent change in LDL-C from baseline to Day 57; LDL-C determined using the Friedewald formula
| percent change from baseline | Obicetrapib Monotherapy | Ezetimibe Monotherapy |
|---|---|---|
| Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib Monotherapy Compared to Ezetimibe Monotherapy [Friedewald] | -34.40 (-57.0 to 23.8) | -14.80 (-51.9 to 59.1) |
LS Mean percent change in LDL-C from baseline to Day 57; LDL-C calculated using the Friedewald formula
| percent change from baseline | Obicetrapib Monotherapy | Ezetimibe Monotherapy |
|---|---|---|
| LS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib Monotherapy Compared to Ezetimibe Monotherapy [Friedewald] | -31.99 ± 3.686 | -13.42 ± 3.675 |
Mean percent change in LDL-C from baseline to Day 57; LDL-C determined using the Friedewald formula
| percent change from baseline | Ezetimibe Monotherapy | Placebo |
|---|---|---|
| Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Ezetimibe Monotherapy Compared to Placebo [Friedewald] | -12.69 ± 21.316 | -0.17 ± 12.682 |
Median percent change in LDL-C from baseline to Day 57; LDL-C calculated using the Friedewald formula
| percent change from baseline | Ezetimibe Monotherapy | Placebo |
|---|---|---|
| Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Ezetimibe Monotherapy Compared to Placebo [Friedewald] | -14.80 (-51.9 to 59.1) | -1.40 (-20.9 to 33.6) |
LS Mean percent change in LDL-C from baseline to Day 57; LDL-C calculated using the Friedewald formula
| percent change from baseline | Ezetimibe Monotherapy | Placebo |
|---|---|---|
| LS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Ezetimibe Monotherapy Compared to Placebo [Friedewald] | -13.42 ± 3.675 | 1.37 ± 3.604 |
Mean percent change in LDL-C from baseline to Day 57; LDL-C measured using preparative ultracentrifugation (PUC)
| percent change from baseline | Ezetimibe Monotherapy | Placebo |
|---|---|---|
| Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Ezetimibe Monotherapy Compared to Placebo [PUC] | -13.68 ± 19.573 | -1.53 ± 15.105 |
Median percent change in LDL-C from baseline to Day 57; LDL-C measured using preparative ultracentrifugation (PUC)
| percent change from baseline | Ezetimibe Monotherapy | Placebo |
|---|---|---|
| Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Ezetimibe Monotherapy Compared to Placebo [PUC] | -14.90 (-46.8 to 46.9) | -2.00 (-24.5 to 35.9) |
LS Mean percent change in LDL-C from baseline to Day 57; LDL-C measured using preparative ultracentrifugation (PUC)
| percent change from baseline | Ezetimibe Monotherapy | Placebo |
|---|---|---|
| LS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Ezetimibe Monotherapy Compared to Placebo [PUC] | -13.55 ± 3.891 | -0.78 ± 4.012 |
Mean percent change in ApoB from baseline to Day 57
| percent change from baseline | Combination Therapy | Ezetimibe Monotherapy |
|---|---|---|
| Mean Percent Change in Apolipoprotein-B (ApoB) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Ezetimibe Monotherapy | -31.62 ± 15.521 | -8.78 ± 14.445 |
Median percent change in ApoB from baseline to Day 57
| percent change from baseline | Combination Therapy | Ezetimibe Monotherapy |
|---|---|---|
| Median Percent Change in Apolipoprotein-B (ApoB) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Ezetimibe Monotherapy | -34.75 (-53.0 to 8.9) | -8.90 (-45.4 to 32.3) |
LS Mean Percent change in ApoB from baseline to Day 57
| percent change from baseline | Combination Therapy | Ezetimibe Monotherapy |
|---|---|---|
| LS Mean Percent Change in Apolipoprotein-B (ApoB) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Ezetimibe Monotherapy | -29.73 ± 2.730 | -8.92 ± 2.675 |
Collected over From first dose of study drug through Week 16. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/28 (0%) | 0/28 (0%) | 6/28 (21.4%) |
| Combination Therapy | 0/27 (0%) | 0/27 (0%) | 9/27 (33.3%) |
| Obicetrapib Monotherapy | 0/28 (0%) | 0/28 (0%) | 4/28 (14.3%) |
| Ezetimibe Monotherapy | 0/28 (0%) | 2/28 (7.1%) | 8/28 (28.6%) |
| Event | Placebo | Combination Therapy | Obicetrapib Monotherapy | Ezetimibe Monotherapy |
|---|---|---|---|---|
| HyperventilationRespiratory, thoracic and mediastinal disorders | 0/28 | 0/27 | 0/28 | 1/28 |
| Multiple fracturesInjury, poisoning and procedural complications | 0/28 | 0/27 | 0/28 | 1/28 |
| Event | Placebo | Combination Therapy | Obicetrapib Monotherapy | Ezetimibe Monotherapy |
|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 0/28 | 2/27 | 0/28 | 2/28 |
| HeadacheNervous system disorders | 1/28 | 1/27 | 0/28 | 2/28 |
| Abdominal painGastrointestinal disorders | 0/28 | 1/27 | 0/28 | 0/28 |
| Upper respiratory tract infectionInfections and infestations | 0/28 | 1/27 | 1/28 | 0/28 |
| InfluenzaInfections and infestations | 0/28 | 1/27 | 0/28 | 0/28 |
| DizzinessNervous system disorders | 0/28 | 1/27 | 0/28 | 0/28 |
| Back painMusculoskeletal and connective tissue disorders | 0/28 | 1/27 | 0/28 | 0/28 |
| SARS-CoV-2 test positiveInvestigations | 0/28 | 1/27 | 0/28 | 0/28 |
| Decreased appetiteMetabolism and nutrition disorders | 0/28 | 1/27 | 0/28 | 0/28 |
| HypertensionVascular disorders | 0/28 | 1/27 | 0/28 | 0/28 |
The study was revised from a 12-week treatment period to an 8-week treatment period in response to the global COVID-19 pandemic. Baseline Population is defined as all participants who received at least one dose of study drug and had a baseline value for LDL-C assessment.
| Age, Continuous(years) | Placebo | Combination Therapy | Obicetrapib Monotherapy | Ezetimibe Monotherapy | Total |
|---|---|---|---|---|---|
| Mean | 54.5 ± 9.81 | 53.5 ± 11.43 | 59.1 ± 7.50 | 54.4 ± 9.55 | 55.4 ± 9.78 |
| Sex: Female, Male(Participants) | Placebo | Combination Therapy | Obicetrapib Monotherapy | Ezetimibe Monotherapy | Total |
|---|---|---|---|---|---|
| Female | 16 | 16 | 14 | 14 | 60 |
| Male | 12 | 11 | 14 | 14 | 51 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Combination Therapy | Obicetrapib Monotherapy | Ezetimibe Monotherapy | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 1 | 1 |
| Not Hispanic or Latino | 26 | 26 | 27 | 25 | 104 |
| Unknown or Not Reported | 2 | 1 | 1 | 2 | 6 |
| Race (NIH/OMB)(Participants) | Placebo | Combination Therapy | Obicetrapib Monotherapy | Ezetimibe Monotherapy | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 3 | 5 | 4 | 4 | 16 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 1 | 0 | 2 |
| White | 24 | 22 | 23 | 24 | 93 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Baseline Low-Density Lipoprotein Cholesterol (LDL-C) Values(milligrams per deciliter (mg/dL)) | Placebo | Combination Therapy | Obicetrapib Monotherapy | Ezetimibe Monotherapy | Total |
|---|---|---|---|---|---|
| Mean | 136.8 ± 19.86 | 132.2 ± 27.48 | 127.5 ± 20.87 | 128.0 ± 22.33 | 131.13 ± 22.64 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2021 to primary completion in May 2021, 2 months.
Results were first posted in Apr 2024, 2 years 11 months after primary completion.
Of 41 industry-sponsored phase 2 interventional studies under Hypercholesterolemia, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 14. This study's 2 months is below that.
Counting every sponsor, half of 48 studies reached it within 10 months; a quarter within 7 and three quarters within 18.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: TA-8995 · Ezetimibe
NewAmsterdam Pharma